Cargando…

Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Detalles Bibliográficos
Autor principal:	Tsang, Vivian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093315/ https://www.ncbi.nlm.nih.gov/pubmed/25031945

Ejemplares similares

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
por: Donato, Eva M, et al.
Publicado: (2018)

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
por: Chen, Xueyan, et al.
Publicado: (2013)

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
por: Chen, Robert, et al.
Publicado: (2016)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
por: Agrusa, Jennifer E., et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
por: Ishizawa, Kenichi, et al.
Publicado: (2019)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
por: Onaka, Takashi, et al.
Publicado: (2018)

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
por: Şahin, Mustafa, et al.
Publicado: (2021)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2018)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
por: Stack, Anthony, et al.
Publicado: (2019)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with RUNX3 overexpression
por: Yamashita, Yusuke, et al.
Publicado: (2020)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin
por: Meconi, Federico, et al.
Publicado: (2019)

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
por: Scott, Lesley J.
Publicado: (2017)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
por: Uchimura, Ayana, et al.
Publicado: (2022)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin
por: Stack, Anthony, et al.
Publicado: (2020)

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2014)

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
por: Izutsu, Koji, et al.
Publicado: (2021)

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
por: Heidegger, Simon, et al.
Publicado: (2014)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
por: Hux, Margaret, et al.
Publicado: (2016)

A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
por: Cao, Zhi-Gang, et al.
Publicado: (2013)

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
por: Jo, Tatsuro, et al.
Publicado: (2020)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
por: Raymakers, A. J. N., et al.
Publicado: (2020)

Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
por: Hegerova, Livia, et al.
Publicado: (2017)

Vaginal ALK-positive anaplastic large cell lymphoma treated with brentuximab vedotin: a case report and literature review
por: Cortez, Anita Cassoli, et al.
Publicado: (2022)

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023)

Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
por: Cunha Pereira, Tatiana, et al.
Publicado: (2020)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma
por: Tama, Elif, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bc4kvlatgn6tpt9uosse0715pg